Profile data is unavailable for this security.
About the company
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
- Revenue in USD (TTM)2.20m
- Net income in USD-125.38m
- Incorporated2015
- Employees82.00
- LocationPraxis Precision Medicines Inc99 High Street, 30th FloorBOSTON 02110United StatesUSA
- Phone+1 (617) 300-8460
- Fax+1 (302) 655-5049
- Websitehttps://praxismedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | 288.00k | -218.13m | 762.68m | 96.00 | -- | 1.99 | -- | 2,648.19 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 765.86m | 164.00 | -- | 3.83 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 766.23m | 159.00 | -- | 1.14 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 775.17m | 300.00 | -- | 2.17 | -- | 4.05 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| 89bio Inc | 0.00 | -165.03m | 777.23m | 70.00 | -- | 1.47 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 777.80m | 234.00 | -- | 3.19 | -- | 1,316.07 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.30m | 806.31m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Evolus Inc | 219.70m | -60.00m | 809.55m | 279.00 | -- | 43.66 | -- | 3.68 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Praxis Precision Medicines Inc | 2.20m | -125.38m | 811.94m | 82.00 | -- | 2.74 | -- | 369.90 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 839.29m | 74.00 | -- | 2.48 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 843.64m | 168.00 | -- | 1.84 | -- | 20.80 | -3.36 | -3.36 | 0.5934 | 6.46 | 0.0775 | -- | 7.09 | 241,428.60 | -39.22 | -47.40 | -43.89 | -54.18 | -- | -- | -506.16 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 850.87m | 309.00 | -- | 1.14 | -- | 24.09 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Tyra Biosciences Inc | 0.00 | -75.45m | 852.20m | 49.00 | -- | 2.18 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 860.43m | 24.00 | -- | 3.83 | -- | 86,042.98 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Data as of May 31 2024. Currency figures normalised to Praxis Precision Medicines Inc's reporting currency: US Dollar USD
47.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 31 Mar 2024 | 1.39m | 8.15% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 1.31m | 7.67% |
| Point72 Asset Management LPas of 31 Mar 2024 | 1.02m | 5.97% |
| RA Capital Management LPas of 31 Mar 2024 | 828.38k | 4.85% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 821.59k | 4.81% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 739.07k | 4.33% |
| Verition Fund Management LLCas of 31 Mar 2024 | 545.41k | 3.19% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 536.00k | 3.14% |
| PFM Health Sciences LPas of 31 Mar 2024 | 477.61k | 2.80% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 442.57k | 2.59% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
